homepage-top-section

The deal also provides Gilead with an exclusive option to acquire the remaining stake in Pionyr for around $315m. The shareholders of Pionyr will secure up to an

Under the strategic collaboration, the companies will develop and commercialise compounds in Takeda’s early-to-mid-stage psychiatry pipeline. As part of the deal, Neurocrine has secured an exclusive licence for

Eli Lilly’s partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising antibody treatment, known as JS016, to treat Covid-19 disease. Junshi

The regulator has approved a supplemental new drug application (sNDA) for Recarbrio to treat patients 18 years of age and older with HABP/VABP caused due to susceptible Gram-negative

The partnership will combine Accent’s expertise in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s advanced knowledge in oncology. Accent Therapeutics CEO Shakti Narayan

The approval, which is based on results from the phase 3 BEACON CRC trial, enables to market Braftovi plus cetuximab in 27 EU member states, as well as

The regulator has provided the company with the permission to submit an investigational new drug application (IND) to use FSD-201 for the treatment of Covid-19, the disease resulted

The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s